Back to Search Start Over

Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.

Authors :
Jayasekera, Jinani
Schechter, Clyde B
Sparano, Joseph A
Jagsi, Reshma
White, Julia
Chapman, Judith-Anne W
Whelan, Timothy
Anderson, Stewart J
Fyles, Anthony W
Sauerbrei, Willi
Zellars, Richard C
Li, Yisheng
Song, Juhee
Huang, Xuelin
Julian, Thomas B
Luta, George
Berry, Donald A
Feuer, Eric J
Mandelblatt, Jeanne
Group, CISNET-BOLD Collaborative
Source :
JNCI: Journal of the National Cancer Institute. Dec2018, Vol. 110 Issue 12, p1370-1379. 10p. 1 Diagram, 4 Charts, 1 Graph.
Publication Year :
2018

Abstract

<bold>Background: </bold>Radiotherapy after breast conservation has become the standard of care. Prior meta-analyses on effects of radiotherapy predated availability of gene expression profiling (GEP) to assess recurrence risk and/or did not include all relevant outcomes. This analysis used GEP information with pooled individual-level data to evaluate the impact of omitting radiotherapy on recurrence and mortality.<bold>Methods: </bold>We considered trials that evaluated or administered radiotherapy after lumpectomy in women with low-risk breast cancer. Women included had undergone lumpectomy and were treated with hormonal therapy for stage I, ER+ and/or PR+, HER2- breast cancer with Oncotype scores no greater than 18. Recurrence-free interval (RFI), type of RFI (locoregional or distant), and breast cancer-specific and overall survival were compared between no radiotherapy and radiotherapy using adjusted Cox models. All statistical tests were two-sided.<bold>Results: </bold>The final sample included 1778 women from seven trials. Omission of radiotherapy was associated with an overall adjusted hazard ratio of 2.59 (95% confidence interval [CI] = 1.38 to 4.89, P = .003) for RFI. There was a statistically significant increase in any first locoregional recurrence (P = .001), but not distant recurrence events (P = .90), or breast cancer-specific (P = .85) or overall survival (P = .61). Five-year RFI rate was high (93.5% for no radiotherapy vs 97.9% for radiotherapy; absolute reduction = 4.4%, 95% CI = 0.7% to 8.1%, P = .03). The effects of radiotherapy varied across subgroups, with lower RFI rates for those with Oncotype scores of less than 11 (vs 11-18), older (vs younger), and ER+/PR+ status (vs other).<bold>Conclusions: </bold>Omission of radiotherapy in hormone-sensitive patients with low recurrence risk may lead to a modest increase in locoregional recurrence event rates, but does not appear to increase the rate of distant recurrence or death. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00278874
Volume :
110
Issue :
12
Database :
Academic Search Index
Journal :
JNCI: Journal of the National Cancer Institute
Publication Type :
Academic Journal
Accession number :
133601193
Full Text :
https://doi.org/10.1093/jnci/djy128